Carlotta Ranieri

In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS)

Carlotta Ranieri, Silvia Di Tommaso, Daria Carmela Loconte et al. · Neurogenetics · 2018 · 83 citations · Full text

Medicine, Molecular Medicine, Oncology +15

Clinical experience with the AKT1 inhibitor miransertib in two children with PIK3CA-related overgrowth syndrome

Karina Forde, Nicoletta Resta, Carlotta Ranieri et al. · Orphanet Journal of Rare Diseases · 2021 · 74 citations · Full text

Medicine, Pediatrics, Pharmacology +13

Genotypes and phenotypes heterogeneity in PIK3CA-related overgrowth spectrum and overlapping conditions: 150 novel patients and systematic review of 1007 patients with PIK3CA pathogenetic variants

Alessandro Mussa, Chiara Leoni, Matteo Iacoviello et al. · Journal of Medical Genetics · 2022 · 51 citations · Full text

Life Sciences, Genetics, Molecular Genetics +17

First evidence of a therapeutic effect of miransertib in a teenager with Proteus syndrome and ovarian carcinoma

Chiara Leoni, Giuseppe Gullo, Nicoletta Resta et al. · American Journal of Medical Genetics Part A · 2019 · 49 citations

Medicine, Gynecology, Oncology +17

Kaposiform hemangioendothelioma further broadens the phenotype of <scp>PIK3CA</scp> ‐related overgrowth spectrum

Diana Carli, Silvia Kalantari, Rosaria Manicone et al. · Clinical Genetics · 2021 · 21 citations

Medicine, Oncology, Pathology +17